Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel

Executive Summary

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.

You may also be interested in...



JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.

NuVasive Selling Titanium-Based Precice Orthopedic Devices Again, Launches Recall To Update IFU

NuVasive Inc. is marketing its Precice specialized orthopedic devices made of titanium once again after voluntarily pulling them from the market in April over concerns about the safety of the steel-based version of the product. The firm also initiated a recall to address changes in the instructions for use for titanium Precice.

Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products

The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT144941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel